Risk Factors for Immunotherapy-related Adverse Events (IrAE) in Patients Treated With Immune Checkpoint Inhibitors

Am J Clin Oncol. 2023 Apr 1;46(4):183-184. doi: 10.1097/COC.0000000000000984. Epub 2023 Mar 24.

Authors

Matthew J Hadfield¹, Hetal Mistry¹, Ari Pelcovits¹, Rani Bansal², Sarah Andrea³, Adel Chergui¹, Kristy Ramphal¹, Matthew Austin⁴, Humera Khurshid¹

Affiliations

¹ Department of Medical Oncology, Brown University/Alpert School of Medicine, Providence, RI.
² Department of Medical Oncology, Duke University, Durham, NC.
³ OHSU-PSU School of Public Health, Portland, OR.
⁴ Department of Medical Oncology, Yale New Haven Cancer Center, New Haven, CT.

PMID: 36959209
DOI: 10.1097/COC.0000000000000984

No abstract available

Publication types

Letter

MeSH terms

Antineoplastic Agents, Immunological* / adverse effects
Humans
Immune Checkpoint Inhibitors / therapeutic use
Immunotherapy / adverse effects
Neoplasms* / drug therapy
Neoplasms* / etiology
Retrospective Studies
Risk Factors

Substances

Immune Checkpoint Inhibitors
Antineoplastic Agents, Immunological